This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: acute coronary syndrome

October 2023 Br J Cardiol 2023;30:152 doi:10.5837/bjc.2023.030

Type of thrombus, no reflow and outcomes of coronary intervention in ACS patients: OCT-guided study

Mostafa Abdelmonaem, Mohamed Farouk, Ahmed Reda

Abstract

Introduction Acute coronary events are commonly caused by plaque rupture, erosion and, infrequently, calcific nodules. In the majority of patients with acute coronary syndrome (ACS), occlusive or sub-occlusive thrombus on top of plaque deformation is the main angiographic finding. Resolving acute thrombotic occlusion remains the cornerstone step in restoring adequate coronary perfusion. Blind dealing with thrombi, depending only on angiography, may be an obstacle to optimal myocardial perfusion and increase in-hospital morbidity and mortality.1–4 In the past, intravascular ultrasound (IVUS) and, more recently, optical coherence tomography (

| Full text

May 2023 Br J Cardiol 2023;30:79–80 doi:10.5837/bjc.2023.015

Concurrent left ventricular and left anterior coronary artery thrombus: is COVID-19 an innocent bystander?

Vincenzo Somma, Anthony Brennan, Francis Ha, Adam Trytell, Khoa Phan, Kegan Moneghetti

Abstract

Introduction Myocarditis is a known complication of COVID-19, however, recently concerns have been raised regarding myocardial injury in the presence of a substantial coronary thrombus burden, in combination with atherosclerotic plaque.1,2 Widespread community transmission of COVID-19 has led to some presentations of myocardial infarction associated with active COVID-19 infection.1 We present the angiographic findings of such a case with a heavy burden of thrombus, despite only minor obstructive coronary disease. Case presentation A 36-year-old man was admitted to a local hospital with respiratory failure secondary to COVID-19 pneumonia. Init

| Full text

November 2022 Br J Cardiol 2022;29:129–31 doi:10.5837/bjc.2022.035

Secondary prevention lipid management following ACS: a missed opportunity?

Zahid Khan, Roby Rakhit

Abstract

European Society of Cardiology (ESC) guidelines recommend low-density lipoprotein (LDL) below 1.4 mmol/L in patients post ACS, which differs from UK National Institute for Health and Care Excellence (NICE) guideline recommendations of 1.8 mmol/L and 1.4 mmol/L in very-high-risk patients only.6,7 The fifth European survey of Cardiovascular Disease prevention and Diabetes (EUROASPIRE V) survey showed that only 30% of post-ACS patients had low-density lipoprotein cholesterol (LDL-C) levels <1.8 mmol/L one year after discharge.8 The ACS EuroPath survey showed a considerable lack of physicians’ compliance with guidelines in managing lipid low

| Full text

December 2020 Br J Cardiol 2020;27:141–2 doi:10.5837/bjc.2020.039

C-reactive protein: a prognostic indicator for sudden cardiac death post-myocardial infarction

Jordan Faulkner, Francis A Kalu

Abstract

Introduction Primary percutaneous coronary intervention (pPCI) and stenting are considered first-line management of ST-elevation myocardial infarction (STEMI).1 There is a well-recognised inflammatory component to ischaemic heart disease (IHD), and, thus, C-reactive protein (CRP) has been implicated as a poor prognostic indicator for stent re-stenosis, cardiovascular mortality and all-cause mortality post-myocardial infarction (MI).1,2 Case An 87-year-old man presented to Accident and Emergency (A&E) for “a one day history of severe neck/parietal headache on background of recent discharge from hospital with an MI”. Past medical histor

| Full text

November 2019 Br J Cardiol 2019;26:141–4 doi:10.5837/bjc.2019.041

Lipid testing and treatment after acute myocardial infarction: no flags for the flagship

Louise Aubiniere-Robb, Jonathan E Dickerson, Adrian J B Brady

Abstract

Introduction Cholesterol is a key risk factor for atheroma and coronary heart disease. The evidence-base for high-intensity lipid-lowering therapy in secondary prevention of cardiovascular disease is unequivocal.1-4 Despite the introduction of novel drugs, including ezetimibe5,6 and monoclonal antibodies,7 statins remain first-line therapy.8,9 Statins decrease hepatic cholesterol synthesis by competitively inhibiting 5-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase receptors, as they have an affinity up to 10,000 times greater than the natural substrate.10 Through reducing intra-cellular cholesterol concentration, statins up-regulate

| Full text

May 2019 Br J Cardiol 2019;26:59–62 doi:10.5837/bjc.2019.018

Rapid rule-out of NSTEMI: clinical characteristics and outcome of patients with undetectable troponin

Sally Youssef, Mariam Ali, Kim Heathcote, Alistair Mackay, Chris Isles

Abstract

Introduction Most patients presenting as an emergency with chest pain do not have myocardial infarction (MI),1 which must, nevertheless, be ruled out in order to reassure and discharge from hospital. High-sensitivity cardiac troponin T (hs-TnT) and troponin I (hs-TnI) have streamlined the assessment and management of chest pain, as a rapid rule out of MI is now possible, particularly if hs-TnT or hs-TnI are undetectable at presentation.2-8 Undetectable troponin cannot, however, be used to exclude unstable angina, which by definition is not associated with a troponin rise.9 It is for this reason that physicians and cardiologists may be reluct

| Full text

May 2019 Br J Cardiol 2019;26:50

Quick takes from ACC.19: The American College of Cardiology 68th Annual Scientific Sessions

Gerald Chi, Syed Hassan Abbas Kazmi, C. Michael Gibson

Abstract

ACC.19 was held in New Orleans, US PARTNER 3 and Evolut Low Risk add to evidence base for TAVR Prior literature suggests that transcatheter aortic-valve replacement (TAVR) is non-inferior or even superior to standard surgical aortic-valve replacement (SAVR) among high and intermediate surgical risk patients with aortic stenosis (AS). Two pivotal studies have now addressed the efficacy and safety of TAVR in AS patients at low mortality risk from surgery. PARTNER 3 (ClinicalTrials.gov: NCT02675114) was an open-label trial that randomised 1,000 subjects with severe AS at low mortality risk from surgery into either TAVR with a third-generation ba

| Full text

October 2018 Br J Cardiol 2018;25:143–6 doi:10.5837/bjc.2018.028

New-onset giant T-wave inversion with prolonged QT interval: shared by multiple pathologies

Debjit Chatterjee, Priya Philip, Kay Teck Ling

Abstract

Introduction We published three cases with electrocardiogram (ECG) manifestation of new-onset giant T-wave inversion and QT prolongation associated with significant left main/left anterior descending artery disease in 2015.1 Since this publication we prospectively looked for patients in coronary care and the cardiology ward in our hospital who were admitted with, or developed during hospital stay, the above ECG changes. We found 10 patients with similar ECG features between March 2016 and February 2018. Four cases were associated with significant left main stem and/or left anterior descending coronary artery disease. Two cases were due to Tak

| Full text

January 2018 doi:10.5837/bjc.2018.004 Online First

Recognition and management of aVR STEMI: a retrospective cohort study

Ruan Vlok, Joshua Wall, Hannah Kempton, Thomas Melhuish, Astin Lee, Leigh White

Abstract

Figure 1. ST-elevation in aVR Introduction The variety of electrocardiogram (ECG) changes that occur following acute myocardial infarction (AMI), occur in concordance with coronary circulation anatomy. ST-segment elevation in lead aVR can indicate an anterior wall AMI.1,2 However, lead aVR is commonly neglected by clinicians,3 and as such, this may be a potential source of adverse patient outcomes. The aim of this single-centre study is to investigate how proficiently AMIs presenting with aVR ST-elevation are recognised, using ‘door-to-balloon times’ as an outcome measure in patients having primary percutaneous coronary intervention (PCI)

| Full text

November 2017 Br J Cardiol 2017;24:129

REDUCE shows non-inferiority of short versus long DAPT in acute coronary syndrome

BJC Staff

Abstract

The COMBO™ dual therapy stent REDUCE (Short-term Dual Anti Platelet Therapy in Patients with ACS Treated with the COMBO Dual-therapy Stent), a physician-initiated, prospective, multi-centre, randomised study, was conducted in 36 hospitals in Europe and Asia, enrolling a total of 1,496 ACS patients. The study was designed to demonstrate non-inferiority of a strategy of short-term (three months) dual antiplatelet therapy (DAPT) compared to standard 12-month DAPT in patients with ACS treated with a dual-therapy stent. The stent used in the study COMBO™ (OrbusNeich) is a sirolimus-eluting stent with an abluminal biodegradable polymer matrix,

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now